Nightingale has been nominated as a national finalist in the Nordic Startup Awards 2018, an annual competition that recognizes the achievements of startup ecosystems based in the Nordic region.
Nightingale has been nominated as a national finalist in the Nordic Startup Awards 2018, an annual competition that recognizes the achievements of startup ecosystems based in the Nordic region. More than 2,500 nominees have been evaluated by experts and we’re excited to share that we’ve been nominated as one of finalists in the “Startup of the Year” and “Best HealthTech Startup” categories. On top of this, our CEO, Teemu Suna, has been nominated as a “Founder of the Year” finalist.
The winners from the national competition will be announced on 24th September in an event Helsinki and will compete with other national startup winners for the ultimate award at the Grand Nordic Startup Awards Finale in Copenhagen on 30th October.
Public voting has begun and counts as one jury member – you can help Nightingale and Teemu get to the finals by voting below! (requires a Facebook account)
Nightingale is the innovator of an internationally recognized blood analysis technology for early disease detection. Our aim is to solve the growing burden of cardiovascular disease and diabetes, accounting for healthcare costs of over 1.2 trillion euros annually. By providing customers with accurate health data, Nightingale aims to help empower patients to follow-up on their own well-being and take proactive steps to stay healthy.
Last year, Nightingale was selected as one of the winners of MIT’s (Massachusetts's Institute of Technology) Solve competition, hosted at the United Nations HQ. Nightingale has also been awarded as one of the most innovative biotech SMEs in Europe and “Health Innovation” of the Year at the Health Awards 2018.